Cargando…

T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)

BACKGROUND: Clozapine is associated with high rates of obesity and type 2 diabetes (T2DM). Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, can counter clozapine-associated GLP-1 dysregulation. Our randomized, controlled (RCT), open-label, pilot trial of once-weekly extended-release su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siskind, Dan, Russell, Anthony, Kisely, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233862/ http://dx.doi.org/10.1093/schbul/sbaa029.604

Ejemplares similares

T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL
por: Siskind, Dan, et al.
Publicado: (2018)

Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
por: Mayfield, Karla, et al.
Publicado: (2015)

T24. CHANGES IN TELOMERE LENGTH IN YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A 12-MONTHS FOLLOW-UP STUDY
por: Ayora, Mirian, et al.
Publicado: (2020)

T204. CLOZAPINE COMBINATION AND AUGMENTATION STRATEGIES IN PATIENTS WITH SCHIZOPHRENIA –RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT SURVEY AMONG THE TREATMENT RESPONSE AND RESISTANCE IN PSYCHOSIS (TRRIP) WORKING GROUP
por: Wagner, Elias, et al.
Publicado: (2020)

Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
por: Siskind, Dan J., et al.
Publicado: (2016)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

T203. RELEVANT CLOZAPINE BLOOD LEVELS USING A POINT OF CARE TEST (POCT)
por: Kelly, Deanna, et al.
Publicado: (2020)

Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study
por: Spokes, Jessica, et al.
Publicado: (2021)

Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)
por: Siskind, Dan, et al.
Publicado: (2023)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bowden, Sylvie, et al.
Publicado: (2020)

T1. CLINICAL PROFILE AND PREVALENCE OF POSTTRAUMATIC STRESS SYMPTOMS AMONG SERVICE-USERS REFERRED FOR PSYCHOLOGICAL FOLLOW-UP: UTILITY OF ASSESSING SYMPTOMS SEVERITY RANGE
por: Penney, Danielle, et al.
Publicado: (2020)

T52. COGNITION, METACOGNITION AND SOCIAL COGNITION AFTER A FIRST EPISODE PSYCHOSIS. PRELIMINARY RESULTS FROM A 5-YEAR-FOLLOW-UP STUDY
por: Tripoli, Giada, et al.
Publicado: (2020)

T223. MULTIVARIATE PREDICTION OF FOLLOW UP SOCIAL AND OCCUPATIONAL OUTCOME IN CLINICAL HIGH-RISK INDIVIDUALS BASED ON GRAY MATTER VOLUMES AND HISTORY OF ENVIRONMENTAL ADVERSE EVENTS
por: Antonucci, Linda, et al.
Publicado: (2020)

M89. PHARMACOLOGICAL INTERVENTIONS FOR SMOKING CESSATION AMONG PEOPLE WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Siskind, Dan, et al.
Publicado: (2020)

T225. THE CHANGE OF ADMISSION PATTERN IN PSYCHIATRIC INPATIENTS FOLLOWING REVISION OF MENTAL HEALTH ACT IN KOREA
Publicado: (2020)

Abnormal placental pathology and anti-SARS-CoV-2 transplacental antibody transfer following natural infection
por: Timi, Patience T., et al.
Publicado: (2022)

41.1 WHAT DO META-ANALYSES TELL US ABOUT CLOZAPINE’S EFFICACY AND EFFECTIVENESS FOR TREATMENT REFRACTORY SCHIZOPHRENIA?
por: Siskind, Dan, et al.
Publicado: (2018)

T36. NEURAL CHANGES FOLLOWING A BODY-ORIENTED RESILIENCE THERAPY WITH ELEMENTS OF KICKBOXING FOR INDIVIDUALS WITH A PSYCHOTIC DISORDER: A RANDOMIZED CONTROLLED TRIAL
por: van der Stouwe, Elisabeth, et al.
Publicado: (2020)

T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
por: Merritt, Kate, et al.
Publicado: (2020)

T86. RELEVANCE OF CANNABIS USE AS A PREDICTOR OF CLINICAL OUTCOME IN FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER PATIENTS OVER 24 MONTHS OF TREATMENT
por: Scheffler, Frederika, et al.
Publicado: (2020)

T46. THE EFFECT OF COMPREHENSIVE COGNITIVE REMEDIATION IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: A SINGLE-BLIND, RANDOMISED, CLINICAL TRIAL (FOCUS)
por: Birkedal Glenthoej, Louise, et al.
Publicado: (2020)

T12. THE RELATIONSHIP OF INTESTINAL PERMEABILITY FACTORS WITH SOCIODEMOGRAPHIC AND PHYSICAL HEALTH FACTORS AND PANSS SCORES IN SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS
por: Borkent, Jenny, et al.
Publicado: (2020)

Treatment strategies for clozapine-induced hypotension: a systematic review
por: Tanzer, Timothy David, et al.
Publicado: (2022)

T58. EFFECTIVENESS OF ORALLY ADMINISTERED CO-ENZYME Q10 FOR SCHIZOPHRENIA: COGNITIVE, FUNCTIONAL AND BIOCHEMICAL OUTCOMES FROM A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED TRIAL
por: Hargreaves, April, et al.
Publicado: (2020)

T29. CHILDHOOD PSYCHOPATHOLOGY ACROSS 12 YEARS PREDICTS ADULT PSYCHOTIC-LIKE EXPERIENCES: A PARALLEL TWO-PART PIECEWISE LATENT GROWTH CURVE MODEL
por: Ka-Yee Wong, Keri, et al.
Publicado: (2020)

T38. POSTER PRESENTATION: HAMLETT: HANDLING ANTIPSYCHOTIC MEDICATION, A LONGTERM EVALUATION OF TARGETED TREATMENT A PRAGMATIC SINGLE-BLIND RANDOMISED CONTROLLED TRIAL OF CONTINUATION VERSUS DISCONTINUATION OF PSYCHOTIC MEDICATION
por: van‘t Hag, Erna
Publicado: (2020)

Benefits following community treatment orders have an inverse relationship with rates of use: meta-analysis and meta-regression
por: Kisely, Steve, et al.
Publicado: (2023)

904 Prenatal genetic diagnostic testing during the COVID-19 pandemic
por: Baptiste, Caitlin, et al.
Publicado: (2021)

Codex alimentarius = Commision du codex alimentarius = Comisión del codex alimentarius
Publicado: (1994)

CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2021)

CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2018)

S1. CLOZAPINE RECHALLENGE FOLLOWING NEUTROPENIA USING GRANULOCYTE COLONY-STIMULATING FACTOR: A QUEBEC CASE SERIES
por: Béchard, Laurent, et al.
Publicado: (2020)

T27. COGNITIVE RESERVE IN CHILD AND ADOLESCENT OFFSPRING OF PATIENTS DIANOSED WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
por: De la Serna, Elena, et al.
Publicado: (2020)

T22. RELATIONSHIP BETWEEN CORTICAL THICKNESS AND FUNCTIONAL OUTCOME IN INDIVIDUALS AT RISK OF PSYCHOSIS
por: Sasabayashi, Daiki, et al.
Publicado: (2020)

T239. INDIVIDUAL AND NEIGHBORHOOD PREDICTORS OF OUTPATIENT MENTAL HEALTH SERVICE UTILIZATION AMONG PERSONS WITH SERIOUS MENTAL ILLNESSES
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

T69. CORRELATION BETWEEN PERFORMANCE-BASED AND INTERVIEW-BASED COGNITIVE MEASUREMENTS IN PATIENTS WITH SCHIZOPHRENIA
por: Jeon, Dong-wook, et al.
Publicado: (2020)

T6. ASSOCIATION BETWEEN THE USE OF AN ANTIPSYCHOTIC DRUG AND CHANGES IN LIPID PROFILE: A META-ANALYSIS
por: Brierley, Beverley, et al.
Publicado: (2020)

T31. TIME TO TALK MENTAL HEALTH IN DUBAI: DESCRIBING A SAMPLE OF ADOLESCENT HELP-SEEKERS ACCESSING MENTAL HEALTH SERVICES
por: Barbato, Mariapaola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_32m7vajsmefi3jhh05afs138mb